Zimmer Biomet Holdings, Inc. (ZBH, Financial) has successfully completed its merger with Paragon 28, Inc., a strategic move that positions the company for enhanced growth and market presence. The merger was finalized on April 21, 2025, with Paragon 28 now operating as a wholly owned subsidiary of Zimmer Biomet's subsidiary, Zimmer, Inc.
Under the terms of the merger agreement, each outstanding share of Paragon 28 common stock was converted into the right to receive $13.00 in cash, along with one contractual contingent value right. This acquisition is expected to bolster Zimmer Biomet's capabilities and offerings in the medical device sector, particularly in the foot and ankle market where Paragon 28 has established a strong foothold.
The completion of this merger marks a significant milestone for Zimmer Biomet as it continues to expand its portfolio and strengthen its competitive edge in the industry. The company aims to leverage Paragon 28's innovative solutions and expertise to deliver enhanced value to its stakeholders.
For more detailed insights and analysis on this strategic acquisition, visit GuruFocus.com.
Should you invest in Zimmer Biomet Holdings Inc (ZBH, Financial) right now? Before you do it, it’s important to understand the business profitability and stock valuations, and find out what the warning signs are about. See the in-depth Zimmer Biomet Holdings Inc (ZBH) stock research here.
